Invoke Bio designs personalised neoantigen vaccines in whatever form suits the patient, peptide, DNA or mRNA, using a prediction engine it says picks tumour targets with three times the accuracy of industry baselines.
Invoke Bio's immunogenicity prediction engine identifies tumour neoantigens for personalised vaccines and is modality-agnostic, supporting peptide, DNA and mRNA formats. Future of Cancer Care Today lists it as patient-orderable.
Shares Future of Cancer Care Today (FCCT), Personalised neoantigen (mRNA) vaccines and the tag fcct-directory.
Shares Future of Cancer Care Today (FCCT), Personalised neoantigen (mRNA) vaccines and the tag fcct-directory.
Shares Future of Cancer Care Today (FCCT) and the tag fcct-directory.
Shares Future of Cancer Care Today (FCCT) and the tag fcct-directory.
Shares Future of Cancer Care Today (FCCT) and the tag fcct-directory.
Shares Future of Cancer Care Today (FCCT) and the tag fcct-directory.
Shares Future of Cancer Care Today (FCCT) and the tag fcct-directory.
Shares Future of Cancer Care Today (FCCT) and the tag fcct-directory.